Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia 2 Hematologic Neoplasms 2 Thyroid Nodule 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Neoplasms 1 Cardiotoxicity 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Carboplatin 346 Cisplatin 240 Paclitaxel 208 Radiotherapy 207 Pemetrexed 190 Docetaxel 170 Gemcitabine 158 pembrolizumab 147 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 102 Etoposide 99 Bevacizumab 96 Specimen Handling 84 Nivolumab 77 Radiosurgery 74 durvalumab 73 Blood Specimen Collection 65 Drug Therapy 61 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 48 atezolizumab 45 Biopsy 43 Radiation 42 Irinotecan 42 Topotecan 39 Standard of Care 39 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Blood Cell Count × Clear all

NCT03749512 2018-11-21

NLCR in Prediction of the Grade of Lung Tumor.

Medical University of Silesia

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡